Compounds > 2-n-propylquinoline
Page last updated: 2024-11-06

2-n-propylquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-propylquinoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74166
CHEMBL ID354607
SCHEMBL ID725176
MeSH IDM0298468

Synonyms (11)

Synonym
2-propylquinoline
quinoline, 2-propyl-
AKOS006370675
2-n-propylquinoleine
2-propyl-quinoline
CHEMBL354607
1613-32-7
SCHEMBL725176
IZXJPGLOYYDHRM-UHFFFAOYSA-N
DTXSID80167105
2-n-propylquinoline

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetics of 2-n-PQ in rats showed that after an intravenous treatment of the formulation at 10mgkg(-1), the plasma drug concentrations rapidly declined bi-exponentially with a half-life of 58."( In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route.
Balaraman, K; Bories, C; Cojean, S; Figadère, B; Kesavan, V; Loiseau, PM; Moussa, F; Pomel, S; Vacus, J; Vieira, NC, 2015)		0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID776404Drug metabolism in mouse liver microsomes at 1 uM after 30 mins by LC-MS/MS analysis2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID84649Inhibitory activity against human T-lymphotropic virus type 1 (HTLV-1) infected HUT-102 cells at 10 uM2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Substituted quinolines induce inhibition of proliferation of HTLV-1 infected cells.
AID776405Solubility of the compound2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776406Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Leishmania donovani MHOM/IN/80/Dd8 amastigotes2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776408Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse J774A1 cells assessed as parasite growth inhibition after 72 hrs by luciferase reporter gene assay2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776403Drug metabolism in human liver microsomes at 1 uM after 30 mins by LC-MS/MS analysis2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776407Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID1845743Antileishmanial activity against promastigote form of Leishmania braziliensis assessed as parasite growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32A comprehensive review on the biological interest of quinoline and its derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's4 (44.44)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.55 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		2.0610phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.4820phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		210C-nitro compound;
imidazoles		antitubercular agent
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		3.4110ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		210C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
acarbose
[no description available]		3.4110tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
2-phenylquinoline
2-phenylquinoline: structure in first source		2.0110
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.1110cyclodextrin
nadp
[no description available]		2.0110
styrylquinoline
styrylquinoline: structure in first source		2.01102-styrylquinoline
ConditionIndicatedRelationship StrengthStudiesTrials
Human T-lymphotropic Virus 1 Infection
[description not available]		02.0110
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		02.0110
HTLV-I Infections
Diseases caused by HUMAN T-LYMPHOTROPIC VIRUS 1.		02.0110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9740
Black Fever
[description not available]		02.7830
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.7830
Chronic Illness
[description not available]		0210
American Trypanosomiasis
[description not available]		0210
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		0210
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		0210